Released on = April 3, 2006, 11:20 am

Press Release Author = Econ Corporate Services, Inc

Industry = Biotech

Press Release Summary = Biotech and Healthcare Companies Present Potential Solutions
to the Bird Flu

Press Release Body =
Global Demand Supports Development of Avian Flu Treatments and Antiviral Drugs
Biotech and Healthcare Companies Present Potential Solutions to the Bird Flu

POINT ROBERTS, WA, Delta B.C., April 03, 2006 - www.China-AsiaStocks.com (CAS) and
www.BiotechIndustryStocks.com (BIS) , investor and industry news portals for the
China-Asia and biotechnology sectors, feature "Global Demand Boosts Avian Flu
Vaccine Market\", for investors and industry following developments in the vaccine
market. Biotech and Healthcare companies: Bridgetech Holdings International Inc.,
Generex Biotech, AVI Biopharma Inc., Hemispherx Biopharma, Inc, Carrington
Laboratories and Aethlon Medical, discuss unique approaches to this potential global
dilemma and offer insight to possible solutions.

Dr. Carlton Turner, President and CEO of Carrington Laboratories gave an overview on
the market, commenting that, "Policymakers from around the world are responding as
best they can to the threat of an H5 Avian Flu pandemic. The challenge lies in
trying to find the right antigen, producing enough of it to protect the world's
population and then finding a way to deliver it to large populations efficiently."

Michael Chermak, CEO for Bridgetech Holdings International Inc (OTC.PK: BGTH), has
provided insights with respect to the effect the Avian Flu has had on China's
healthcare market, "The impact of the Avian Flu outbreak on the Chinese healthcare
system has been profound. The resulting self examination has created a sense of
urgency, regarding the modernization and improvement of the entire system."

Vice President of Generex (NASDAQ: GNBT) and President of Antigen Express, Dr. Eric
Vonhofe, expressed great confidence in their product, explaining that," Last fall,
the government paid about $100 million for an egg based vaccine, but that will
probably be enough for only about 3 million people. In contrast, our vaccine which
is synthetic can be made on a 100 kg scale quickly, efficiently and at a relatively
inexpensive rate."

AVI Biopharma Inc., a producer of antiviral drugs, has established avian influenza
H5N1 as a priority within the company. Michael Hubbard, Director of Investor
Relations for the company said that, "We are moving as quickly as we can on Avian
Flu, given the urgency. As soon as we have the safety data, we can apply for a new
drug application with the FDA, which we hope to do before year's end." Dr. David
Strayer, Medical Director at Hemispherx Biopharma, Inc. (AMEX: HEB) also pointed out
that, "This area could move very rapidly because there is an urgent need for a
better way to treat and prevent Avian influenza. I think there is great potential
here for our company."

However, antiviral drugs currently being stockpiled as part of a global strategy to
treat Avian Flu may have little therapeutic value once the deadly cytokine store has
been triggered. As explained by James A. Joyce, Chairman and CEO at Aethlon Medican
Inc. (OTCBB: AEMD), "Once a cytokine storm has been triggered, the Hemopurifier
could serve as the first, and perhaps only option for treating H5N1 infected
patients."

To Read "Global Demand Boosts Avian Flu Vaccine Market" In Full Click Here:
http://www.China-AsiaStocks.com/Articles/Avian_Flu.asp

About our CAS and BIS Portals:

www.China-AsiaStocks.com and www.BiotechIndustryStocks.com portals within the
InvestorIdeas.com content umbrella, offer investors research, news and links to
public companies within the China-Asia and Biotechnology sectors. CAS and BIS do not
make recommendations, but offer unique free information portals to research news,
articles, interviews and a growing list of participating public companies in the
China-Asia and biotech industry.

China-AsiaStocks.com includes a comprehensive and growing list of China Asia
Stocks: http://www.China-AsiaStocks.com/Companies/China-AsiaStocks/Stocks_List.asp

To visit our China-Asia portal in Chinese click here:
http://www.china-asiastocks.com/CAS/

Featured Sponsor Participating in the China Asia Market: (CAS is compensated by
Bridgetech Holding International as disclosed in disclaimer.)

Bridgetech Holdings International Inc (OTC.PK: BGTH) a leading distributor of
western based healthcare products and medical technology in China. For more info:
http://www.china-asiastocks.com/CO/BGTH/Default.asp or visit the company\'s website
at www.bthi.com.


Investorideas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp Our sites
do not make recommendations, but offer information portals to research news,
articles, stock lists and recent research. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. We attempt to
research thoroughly, but we offer no guarantees as to the accuracy of information
presented. All Information relating to featured companies is sourced from public
documents and/ or the company and is not the opinion of our web sites. This site is
currently compensated by its \"featured companies.\" Bridgetech Holdings
International, Inc five thousand dollars per month and ten thousand shares of 144
stock as a one time fee .Additionally , Aethlon Medical was a former featured
company on Investorideas.com, please review previous clients disclaimer.

For More Information Contact:

Dawn Van Zant 800-665-0411
Fei Wang 866-948-0848
Email: dvanzant@investorideas.com or fwang@investorideas.com

Web Site: www.InvestorIdeas.com

Source: China-AsiaStocks.com, Bridgetech Holdings International, Generex Biotech,
AVI Biopharma Inc., Hemispherx, Carrington Laboratories and Aethlon Medical





Web Site = http://www.china-asiastocks.com

Contact Details = Dawn Van Zant 800-665-0411
Fei Wang 866-948-0848
Email: dvanzant@investorideas.com or fwang@investorideas.com

Web Site: www.InvestorIdeas.com